Aligos Therapeutics (NASDAQ:ALGS) Announces Earnings Results, Beats Estimates By $0.95 EPS

Aligos Therapeutics (NASDAQ:ALGS) posted its quarterly earnings data on Thursday. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($1.09) by $0.95, FiscalAI reports. The business had revenue of $27.78 million during the quarter, compared to analysts’ expectations of $24.68 million. Aligos Therapeutics had a negative net margin of 241.01% and a negative return on equity of 145.00%.

Aligos Therapeutics Stock Up 1.5%

Shares of ALGS stock opened at $5.59 on Friday. Aligos Therapeutics has a 52 week low of $3.98 and a 52 week high of $13.69. The firm has a 50 day moving average of $5.33 and a 200-day moving average of $6.42. The company has a market cap of $34.60 million, a price-to-earnings ratio of -0.77 and a beta of 2.31.

Institutional Trading of Aligos Therapeutics

Several large investors have recently made changes to their positions in the company. Geode Capital Management LLC lifted its stake in shares of Aligos Therapeutics by 21.3% in the second quarter. Geode Capital Management LLC now owns 34,048 shares of the company’s stock valued at $246,000 after buying an additional 5,978 shares in the last quarter. Susquehanna International Group LLP bought a new stake in Aligos Therapeutics during the 3rd quarter worth approximately $99,000. LPL Financial LLC grew its holdings in Aligos Therapeutics by 19.7% during the fourth quarter. LPL Financial LLC now owns 66,000 shares of the company’s stock worth $615,000 after buying an additional 10,880 shares in the last quarter. HRT Financial LP purchased a new stake in Aligos Therapeutics in the 4th quarter valued at $106,000. Finally, Squarepoint Ops LLC raised its position in Aligos Therapeutics by 64.0% in the 3rd quarter. Squarepoint Ops LLC now owns 30,493 shares of the company’s stock valued at $299,000 after buying an additional 11,904 shares during the last quarter. 60.43% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ALGS has been the subject of a number of recent analyst reports. Wall Street Zen raised shares of Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Sunday, May 17th. Weiss Ratings downgraded Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. Cantor Fitzgerald restated an “overweight” rating on shares of Aligos Therapeutics in a research note on Friday, May 29th. Finally, Lake Street Capital initiated coverage on Aligos Therapeutics in a research report on Thursday, May 28th. They set a “buy” rating and a $45.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $38.50.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical?stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small?molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.